NICE gives Gilead's Sovaldi green light
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal (HTA) body for England and Wales, has issued draft guidance giving the go-ahead for Gilead to sell blockbuster hepatitis C drug Sovaldi (sofosbuvir) via the NHS.